ATE350051T1 - Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten - Google Patents

Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten

Info

Publication number
ATE350051T1
ATE350051T1 AT98944236T AT98944236T ATE350051T1 AT E350051 T1 ATE350051 T1 AT E350051T1 AT 98944236 T AT98944236 T AT 98944236T AT 98944236 T AT98944236 T AT 98944236T AT E350051 T1 ATE350051 T1 AT E350051T1
Authority
AT
Austria
Prior art keywords
disorders
ischemic
treating
disease
cerebral
Prior art date
Application number
AT98944236T
Other languages
English (en)
Inventor
Yoshihiro Yoshida
Shinya Ikematsu
Sadatoshi Sakuma
Munehiro Oda
Original Assignee
Muramatsu Takashi
Yoshihiro Yoshida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Muramatsu Takashi, Yoshihiro Yoshida filed Critical Muramatsu Takashi
Application granted granted Critical
Publication of ATE350051T1 publication Critical patent/ATE350051T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98944236T 1997-09-26 1998-09-25 Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten ATE350051T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27943597 1997-09-26

Publications (1)

Publication Number Publication Date
ATE350051T1 true ATE350051T1 (de) 2007-01-15

Family

ID=17611037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944236T ATE350051T1 (de) 1997-09-26 1998-09-25 Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten

Country Status (9)

Country Link
EP (1) EP1057489B1 (de)
JP (1) JP5400006B2 (de)
KR (1) KR100554294B1 (de)
CN (1) CN1278184A (de)
AT (1) ATE350051T1 (de)
AU (1) AU9185198A (de)
CA (1) CA2304956C (de)
DE (1) DE69836830T2 (de)
WO (1) WO1999016463A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512200A (ja) * 1998-04-17 2002-04-23 アンジオジェニックス， インコーポレイテッド 治療的な脈管形成因子およびその使用方法
EP1097717A4 (de) * 1998-07-10 2004-11-10 Takashi Muramatsu Heilmittel für apoptose assoziierte krankheiten
CN1222296C (zh) 1998-08-24 2005-10-12 村松乔 动脉硬化和ptca术后再狭窄的预防剂/治疗剂
JP4791770B2 (ja) * 2004-12-06 2011-10-12 株式会社セルシグナルズ 心筋障害又は心不全の治療もしくは予防組成物
US8288343B2 (en) 2007-03-30 2012-10-16 National University Corporation Nagoya University Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
WO2014202833A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Treatment of neuronal injuries
WO2019133535A1 (en) 2017-12-27 2019-07-04 Gen Suzuki Cardiosphere-derived cell sheet and methods of making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0827021A (ja) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc 医薬組成物
JP3553655B2 (ja) * 1994-09-02 2004-08-11 喬 村松 ポリペプチドの製造法
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
AU738923C (en) * 1997-03-12 2003-02-20 Takashi Muramatsu Preventive and therapeutic compositions for drug induced nephropathy and hepatopathy

Also Published As

Publication number Publication date
AU9185198A (en) 1999-04-23
CA2304956A1 (en) 1999-04-08
JP2010270156A (ja) 2010-12-02
WO1999016463A1 (fr) 1999-04-08
KR100554294B1 (ko) 2006-02-24
KR20010030716A (ko) 2001-04-16
DE69836830D1 (de) 2007-02-15
DE69836830T2 (de) 2007-10-11
JP5400006B2 (ja) 2014-01-29
EP1057489A1 (de) 2000-12-06
EP1057489A4 (de) 2004-10-27
CN1278184A (zh) 2000-12-27
CA2304956C (en) 2013-12-03
EP1057489B1 (de) 2007-01-03

Similar Documents

Publication Publication Date Title
DK0457295T3 (da) Anvendelse af en modulator af proteinphosphorylering ved behandling af amyloidose knyttet til Alzheimers sygdom
AU4971796A (en) Benzylpiperidines and piperazines as muscarinic antagonists
DE69429527D1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE425750T1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
DE69332462D1 (de) Protease und verwandte DNS-Verbindungen
DE69111642D1 (de) Gabapentin und dessen Derivate zur Behandlung neurodegenerativer Krankheiten.
EP0670731A4 (de) Behandlung der amnesie in der alzheimerschen krankheit hervorgerufen durch die ablagerung vom amyloid g(b) protein.
DE69521700D1 (de) Mittel und methoden zur behandlung von plaque-krankheiten
CA2319308A1 (en) Pharmaceutical agents
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
ATE221662T1 (de) Hemmung von tau-tau-verknüpfung
WO1998005292A3 (en) Piperidine and piperazine derivatives and their use as muscarinic antagonists
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
ATE275415T1 (de) Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
DE69836830D1 (de) Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
AU2001280812A1 (en) Gsk3 polypeptides
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DK0411615T3 (da) 4-(N-Substitueret amino)-2-butynyl-1-urinstoffer og -thiourinstoffer og derivater deraf som centralt virkende muscariniske midler
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
TR23211A (tr) Yeni suebstitueye n-heterosiklik-suebstitueye fenil)-n'-benzoiluereler,bunlarin hazirlanisi icin usuller ve bunlarin zararlilarin kontiolunda kullanilmalari
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
DE69028603D1 (de) Arzneimittel für bessere gehirnwirkung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties